𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis

✍ Scribed by J.J. Michiels; J. Kutti; P. Stark; M. Bazzan; L. Gugliotta; R. Marchioli; M. Griesshammer; P.J.J. van Genderen; J. Brière; J.J. Kiladjian; T. Barbui; G. Finazzi; N.I. Berlin; T.C. Pearson; A.C. Green; S.M. Fruchtmann; R.T. Silver; E. Hansmann; A. Wehmeier; E. Lengfelder; R. Landolfi; H.M. Kvasnicka; H. Hasselbalch; F. Cervantes; J.T. Reilly; J.-L. Demory; H. Gisslinger; Ph. Guardiola; M.C. Martyré; M.C. Le Bousse-Kerdilès; J. Thiele

Book ID
117454662
Publisher
Elsevier Science
Year
1999
Tongue
English
Weight
748 KB
Volume
54
Category
Article
ISSN
0300-2977

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Leukemogenic risk of hydroxyurea therapy
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
✍ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB 👁 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a